Kesin Pharma announces FDA approval and availability of Likmez oral suspension
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
Phase 3 data expected in the second half of 2024
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
General Medicine grows 5% and Vaccines 10% led by Shingrix
The collaboration brings a seamless digital experience to more formulators worldwide
Lack of technology transfer stands out as a formidable barrier
The newly developed adhesive is available in two different grades. Loctite WT 3001 and Loctite WT 3003 h
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Subscribe To Our Newsletter & Stay Updated